Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Centro Cardiovascular da Universidade de Lisboa, CAML, Faculdade de Medicina da Universidade de Lisboa, Portugal; Cardiology Department, Hospital Santa Maria - Centro Hospitalar Universitário Lisboa Norte (CHULN), Lisbon, Portugal.
Vascul Pharmacol. 2022 Feb;142:106929. doi: 10.1016/j.vph.2021.106929. Epub 2021 Oct 30.
Post-operative atrial fibrillation (POAF) is a relevant complication after surgery. Several studies have shown that POAF has important consequences for long-term morbidity and mortality, by increasing the risk of thromboembolic events. However, the use of oral anticoagulation (OAC) is not well established in this context.
We searched MEDLINE, CENTRAL, PsycInfo and Web of Science for clinical trials and observational studies evaluating anticoagulation vs. no anticoagulation in patients with POAF (after cardiac or non-cardiac surgery). Data were screened and extracted by two independent reviewers. We performed a random- effects model to estimate the pooled odds ratio (OR) with 95% Confidence Intervals (CI), and heterogeneity was evaluated by I statistics. The outcomes of interest were all-cause mortality, thromboembolic events, and bleeding events.
Overall, 10 observational retrospective studies were included: 5 studies with 203,946 cardiac surgery POAF patients, and 5 studies with 29,566 patients with POAF after non-cardiac surgery. In cardiac surgery POAF, the OAC use was associated with lower risk of thromboembolic events (OR 0.68; 95%CI 0.47-0.96, I = 31%; 4 studies) and the bleeding risk was significantly increased (OR 4.30; 95%CI 3.69 to 5.02, 1 study). In non-cardiac surgery POAF, OAC did not significantly reduce the risk of thromboembolic events (OR 0.71, 95%CI 0.33-1.15; I = 79%; 5 studies) but was associated with increased risk of bleeding (OR 1.20, 95%CI 1.10-1.32, I = 0%; 3 studies). Mortality was not significantly reduced in both cardiac and non-cardiac surgery POAF.
Oral anticoagulation was associated with a lower risk of thromboembolic events in patients with POAF following cardiac surgery but not in non-cardiac surgery. Bleeding risk was increased in both settings. The confidence on pooled results is at most low, and further data, namely randomized controlled trials are necessary to derive robust conclusions.
术后心房颤动(POAF)是手术后的一个相关并发症。多项研究表明,POAF 对长期发病率和死亡率有重要影响,增加了血栓栓塞事件的风险。然而,在这种情况下,口服抗凝剂(OAC)的使用尚未得到很好的确立。
我们在 MEDLINE、CENTRAL、PsycInfo 和 Web of Science 中搜索了评估 POAF(心脏或非心脏手术后)患者抗凝与非抗凝的临床试验和观察性研究。数据由两名独立审查员筛选和提取。我们使用随机效应模型来估计合并优势比(OR)及其 95%置信区间(CI),并通过 I 统计量评估异质性。感兴趣的结局是全因死亡率、血栓栓塞事件和出血事件。
共纳入 10 项观察性回顾性研究:5 项研究纳入 203946 例心脏手术后 POAF 患者,5 项研究纳入 29566 例非心脏手术后 POAF 患者。在心脏手术后 POAF 中,OAC 的使用与较低的血栓栓塞事件风险相关(OR 0.68;95%CI 0.47-0.96,I = 31%;4 项研究),出血风险显著增加(OR 4.30;95%CI 3.69 至 5.02,1 项研究)。在非心脏手术后 POAF 中,OAC 并未显著降低血栓栓塞事件风险(OR 0.71;95%CI 0.33-1.15;I = 79%;5 项研究),但与出血风险增加相关(OR 1.20;95%CI 1.10-1.32,I = 0%;3 项研究)。在心脏和非心脏手术后 POAF 中,死亡率均未显著降低。
OAC 与心脏手术后 POAF 患者的血栓栓塞事件风险降低相关,但与非心脏手术后 POAF 患者的血栓栓塞事件风险降低无关。两种情况下出血风险均增加。汇总结果的可信度最多为低,需要进一步的数据,即随机对照试验,以得出可靠的结论。